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LymphomaObjective: To detect accuracy of PET/CT in the initial staging, response during the course
and end of treatment in lymphoma patients compared to contrast CT.
Materials and methods: We studied 50 patients divided into 3 groups with pathologically
proven lymphoma with a mean age = 27. All patients performed CT and PET/CT for initial
staging, during the course of chemotherapy and at the end of treatment.
Results: PET/CT and CECT were agreeable in 75% of cases. 61% during treatment and 41%
agreement at the end of treatment.
Conclusion: PET/CT proved higher sensitivity and specificity over CECT. The major strength
of PET/CT over CECT was its higher ability for detection of extra-nodal sites of lymphoma
and excluding active disease in residual nodal mass lesions on follow-up.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by
Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lymphoma comprises a histological heterogeneous
group of cancers derived from the cells of the immune sys-
tem [1,2]. The hallmark of the disease is the enlargement
and proliferation of lymph nodes or secondary lymphoid
tissues [3,4].
18F-FDG PET/CT has been widely used for staging,
detection of recurrence, and monitoring of treatment
response in patients with Hodgkin’s disease and NHL.
In the past, the imaging evaluation and follow-up of
lymphoma patients were based solely on findings at
contrast-enhanced CT. However, contrast-enhanced CT
has limited sensitivity in detecting lymphomatous involve-
ment of normal-sized lymph nodes, bone marrow, spleen,and extra-nodal tissues [3–6]. The residual lymph node
mass was a commonly encountered diagnostic challenge
because it is difficult at CT to differentiate post-treatment
fibrosis from residual viable malignant changes [6,7].
18F-FDG PET/CT studies show a high sensitivity for
tumor detection and add important functional information
to the inherent anatomic data provided with CT [6]. PET/CT
scanning allows the investigator to visualize and measure
the intensity of residual metabolic activity within a lesion
as well as estimating its size. Hodgkin’s lymphoma is FDG
avid [7,8].
By assessing metabolic activity within a node, 18F-FDG
PET/CT is not directly reliant on nodal size to determine the
presence or absence of malignancy. Nodes that are not
enlarged can be shown to contain tumor on 18F-FDG
PET/CT images, and nodes that are enlarged can be shown
to be reactive in nature. For this reason, PET has been
shown to be more sensitive and specific than CT for iden-
tification of sites of disease. Studies have shown that
Fig. 1. International Harmonization Project Criteria for Assessment of Response to Therapy for Lymphoma [9].
Table 1
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(CT), gallium-67 scintigraphy, and bone scintigraphy in the
staging and treatment evaluation of lymphoma because of
good spatial resolution and the functionality of 18F-FDG
PET/CT scans [8–10].
However limited literature on the use of 18F-FDG PET/
CT evaluating the response to first line of treatment and
follow-up after the end of treatment was found.
Our aim was to show the accuracy and contribution of
18F-FDG PET/CT in the initial staging, response during
treatment and at the end of treatment in lymphoma
patients in comparison with contrast enhanced CT (CECT)
study.Characteristics of the 50 eligible lymphoma patients.
Sex
Male 27/50 (54%)
Female 23/50 (46%)
Histological type
HD 17/50 (34%)
NHL 33/50 (66%)
Histological subtype of HL
Nodular sclerosis (NS) 10/17 (20%)
Mixed cellularity (MC) 5/17 (8%)
Lymphocytic predominance 1/17 (2%)
Lymphocytic depleted 1/17 (2%)
Lymphocytic rich 1/17 (2%)
Histological subtype of NHL
Large B cell 20/33 (40%)
Follicular 5/33 (10%)
Small lymphocytic 3/33 (6%)
Marginal zone 2/33 (4%)
Mantel cell lymphoma 2/33 (4%)
Ann Arbor clinical stage
I 6/50 (10%)
II 11/50 (22%)
III 16/38 (32%)
IV 17/38 (34%)2. Materials and methods
2.1. Study population
This prospective study was conducted on 50 patients
with pathologically proven lymphoma from April 2013 to
August 2015. Their ages ranged from2 up to 70 years (mean
age = 27), including 27males and 23 females. Exclusion cri-
teria were diabetes mellitus and pregnancy. Histopatholog-
ical diagnosis of lymphomawas established in all cases after
biopsy whether surgical or image guided. None of the cases
received any previous oncological treatment. The following
clinical data were obtained from all patients: sex, age, clin-
ical stage, extra-nodal involvement, presence of B symp-
toms, bulky disease, histological subtype according to the
WHO classification, albumin, and erythrocyte sedimenta-
tion rate (ESR), hemoglobin, leukocyte count and
lymphocyte count. All patients included in the study per-
formed CT and 18F-FDG PET/CT for initial staging, after the
first course of chemotherapy (after 4–6 weeks) and after
the end of treatment (after 2–4 months) with medianfollow-up period of 14 months. Stagingwas defined accord-
ing to the Ann Arbor staging system [8]. Treatment of early-
stage disease was given according to the Nordic Lymphoma
Group protocols. The first line of treatmentwas adriamycin,
bleomycin, vinblastine, dacarbazine (ABVD) in standard
doses every 2 weeks (one cycle = 4 weeks) with dose modi-
fication, granulocyte stimulation, or delays depending on
blood counts with or without local radiotherapy. The study
was approved by the ethics committee in ourUniversity and
informed written consents were taken.
Fig. 2. Relation between HD subtypes and SUV uptake.
Fig. 3. Relation between NHD subtypes and SUV uptake.
Table 2
Initial staging by CT versus 18F-FDG PET/CT among 12/50 patients (initial
staging group).
Stage CT stage 18F-FDG PET/CT
I 2 2
II 5 3
III 2 3
IV 2 4
No = 12 P value
Down staging 0 0.004*
No change 4/12 (33%)
Upstaging 8/12 (66%)
* Statistically significant (p < 0.01).
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This prospective study was carried out in the Radiology
departments of Nasser Institute hospitals using GE Discov-
ery 690 PET/CT scanner as well as Siemens Biograph PET/
CT scanner. Prior to the examination, all patients were
asked to fast for 6 h, empty their bladders, remove metallic
items, avoid any kind of strenuous activity, and adminis-
trate 1 l of negative oral contrast agent (5% mannitol) 1 h
before the examination. An I.V. cannula was inserted in
the patient’s arm for administration of 3–7 MBq/kg of
18F-FDG 45–90 min before examination. Then the patients
were instructed to rest in a quiet room, devoid of distrac-
tions, and they were also asked to keep their movements,
including talking, at an absolute minimum.2.3. Imaging protocol
FDG PET/CT scans were performed with integrated PET/
CT scanners (Biograph 16, Siemens). Blood glucose levels
Fig. 4. Initial staging by CT versus 18F-FDG PET/CT among 12/50 patients
(initial staging group).
Fig. 5. CT versus 18F-FDG PET/CT among 12/50 patients (initial staging
group).
Fig. 6. Treatment assessment results of 18F-FDG PET/CT in relation to CT.
Fig. 7. CT versus 18F-FDG PET/CT among 18/50 patients at the end of the
therapy (end of treatment follow-up group).
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Patients were instructed to fast for at least 6 h prior to
the administration of FDG to decrease physiological blood
glucose levels and to reduce serum insulin levels to near
baseline. Patients were not premedicated with muscle
relaxants or sedated. 18F-FDG (0.21 mCi/kg of body weight
[7.78 MBq/kg]) was injected intravenously 45–90 min
prior to image acquisition, and patients were asked to void
their urine immediately before the PET/CT scan. Oralcontrast material was not administered. Once patients
were positioned in the scanner, 125 ml of iohexol (Omni-
paque 240 or 300; GE Healthcare, Princeton, NJ) was
injected intravenously at a flow rate of 4 mU/s. PET and
low-dose CT images (20–120 mA s) in the whole body
were obtained in an arms-up position with scanning times
of approximately 20–30 min. In all patients, emission
images were acquired for 3 min per bed position in a
three-dimensional mode. PET/CT, PET, and CT images were
displayed and reconstructed in the transaxial, coronal, and
sagittal planes.
2.4. Image analysis
All 18F-FDG PET/CT examinations were analyzed by a
consensus of two experienced observers of nuclear medi-
cine physicians and radiologists in a blind fashion. In all
Table 3
Treatment assessment results of CT versus 18F-FDG PET/CT among 18/50
patients (treatment response group).
Stage CT 18F-FDG PET/CT
Complete regression 2/18 (11.11%) 2/18 (11.11%)
Partial regression 3/18 (16.66%) 2/18 (11.11%)
Stationary 4/18 (22.2%) 0/18 (0%)
Progression 9/18 (50%) 14/18 (77.77%)
No = 12 P value
Missed findings 0 0.183
No change 11/18 (61.1%)
Additional findings 7/18 (38.9%)
Fig. 8. A 60 years old female patient with NHL. Axial CT A: showed a rather defined single mildly enhanced gastric mural nodule in the greater curvature,
PET-CT B and C showed 2 18-FDG avid intra mural mass lesions at the greater curvature of the stomach (CT understating).
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max values for each group of enlarged nodes or mass lesion
and comparison of values was done in the follow-up stud-
ies respecting the ROI position as much as possible.
Response evaluation criteria in solid tumours (RECIST)
assessment was used as a secondary method for interpret-
ing findings as positive or negative. According to the IHP
definitions (Fig. 1), residual masses of 2 cm or more in
greatest transverse diameter (GTD) with 18F-FDG activity
visually exceeding that of mediastinal blood pool struc-
tures are considered PET positive, whereas residual masses
1.1–1.9 cm are considered PET positive only if their activity
exceeds surrounding background activity. A smaller resid-
ual mass or a normal-sized lymph node (e.g., <1  1 cm)
should be considered positive for disease if its activity is
higher than that of the surrounding background. If there
was a clearly multifocal increase in FDG uptake in the bone
marrow, the patient was considered as PET positiveexcluding cases where there is diffuse pattern of uptake
of reactive bone marrow hyperplasia after chemotherapy.
In the liver and spleen, focal or diffuse FDG uptake with
activity greater than that in surrounding liver or spleen
parenchyma is considered 18F-FDG PET/CT positive keep-
ing in mind the absence of other confounding factors, such
as physiological hyperplasia after cytokine administration.
The presence of single or multiple foci of clearly elevated
FDG uptake within the bone marrow also is considered
positive for 18F-FDG PET/CT. For follow-up and evaluation
of treatment response, firstly pretreatment baseline PET/
CT was evaluated, followed by analysis of the follow-up
PET images, and complete response (CR) was defined as
disappearance of all detectable disease or lymph nodes
>1.5 cm must decrease to 61.5 cm. Partial response (PR)
was defined as more than 50% in SPD. Stationary (SD)
was defined as less than 50% decrease in SPD. Progressive
disease (PD)/relapse was defined as new lesion or SPD
increase >50% from nadir of any lymph node.
2.5. Standard of references
The final diagnosis made was established in all cases by
means of histopathological examination of surgical or
image guided biopsy.
2.6. Statistical analysis
Data were statistically described in terms of range,
mean ± standard deviation (±SD), median, frequencies
(number of cases) and percentages when appropriate.
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groups was done using Kruskal–Wallis analysis of variance
(ANOVA) test. For comparing categorical data, Chi square
(v2) test was performed. Sensitivity, specificity, positive
and negative predictive values, accuracy, and P value were
calculated to test validity of 18F-FDG PET/CT. Exact test
was used instead when the expected frequency is less than
5. P values less than 0.05 were considered statistically
significant. All statistical calculations were done
using computer programs Microsoft Excel 2007 (Microsoft
Corporation, NY, USA) and SPSS (Statistical Package for the
Social Science).3. Results
The study included 50 patients with pathologically
proved lymphoma with 27.5 mean age. We had 33 cases
who had Non Hodgkin’s disease (66%) and 17 cases who
had Hodgkin’s disease (34%). Most subtypes of HD show
high SUVmax, while in NHD B cell lymphoma shows high
SUVmax in nearly total cases recording in contrast to indo-
lent follicular andmarginal zone lymphoma (Table 1, Figs. 2
and 3).
3.1. In the initial staging
In our study out of the 12 cases came for initial staging,
18F-FDG PET/CT and CECT were concordant in staging of 9Fig. 9. A 25 years old female: pretreatment PET-CT images: A, B, C, and D show
subphrenic lymph node and pulmonary infiltrates (arrows). PET CT images at end o
avid lesions denoting complete remission.cases (75%) while 18F-FDG PET/CT disagreed with CECT in
the initial staging of 3 cases (25%) where it upstaged 3
cases (25%) from stage II to IV. In all the upstaged cases,
the additional value of 18F-FDG PET/CT in all cases was
not in detection of the active subcentimetric lymph nodes
as in the previously described study but in the detection of
the extra-nodal sites of disease that were not determined
by CECT. 18F-FDG PET/CT proved higher sensitivity and
specificity over CECT in our study. The major strengths of
18F-FDG PET/CT over CECT were in its higher ability for
detection of extra-nodal sites of lymphoma. There were
statistically significant results in the initial staging PET-
CT (P value = 0.004) (Table 2, Figs. 4, 5 and 8).3.2. Evaluating response to therapy
In our study, in first follow-up during the course of
chemotherapy, out of the 18 cases, 18F-FDG PET/CT and
CECT were concurrent in results in 13 out of the 18 cases
(68.2%) and discordant in the other 5 cases (31.8%) detailed
as follows: CECT detected complete regression in 2 cases
(11.11%), partial regression in 2 cases (11.11%), stationary
course in 4 cases (22.22%), progression in 9 cases (50%),
while 18F-FDG PET/CT detected complete regression in 2
cases (11.11%), partial regression in 3 cases (16.66%), sta-
tionary course in 0 case (0%), and progression in 14 cases
(77.77%).ed metabolically active 18-FDG avid right supraclavicular lymph node, RT
f therapy: E, F, G, showed total resolution of the previously seen 18-FDG
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PET/CT in all cases was not in detection of the active sub-
centimetric lymph nodes as in the previously described
study but in the detection of the extra-nodal sites of dis-
ease that were not determined by CECT. The difference
was less statistically significant in the follow-up during
treatment in 18F-FDG PET/CT study (P value = 0.138)
(Table 3, Figs. 6, 9 and 10).Table 4
CT versus 18F-FDG PET/CT among 18/50 patients at the end of the therapy
(end of treatment follow-up group).
Stage CT 18F-FDG PET/CT
Complete regression 9/18 (45%) 5/18 (25%)
Partial regression 6/18 (30%) 0/18 (0%)
Stationary 5/18 (25%) 0/18 (0%)
Disease relapse 0/18 (0%) 13/18 (70%)
No = 12 P value
Missed findings staging 0/18 (0%) 0.183
No change 5/18 (25%)
Additional findings 13/18 (70%)3.3. Follow up
Out of 20 cases CECT detected complete regression in 9
cases (45%), partial regression in 6 cases (30%), stationary
course in 5 cases (25%) while 18F-FDG PET/CT detected
complete regression in 5 cases (25%) and disease relapse
in 15 cases (75%). There were statistically significant
results in the follow-up of 6 months after the end of
chemotherapy 18F-FDG PET/CT study (P value = 0.006).
18F-FDG PET/CT proved higher sensitivity and specificity
over CECT in our study which was in keeping with the
results of the other similar studies. The major strengths
of 18F-FDG PET/CT over CECT were in its higher ability to
exclude active disease in addition to its ability for early
detection of relapse sites which also can help in directingFig. 10. A seven year old boy: pretreatment Axial CT and axial PET-CT images: A
mass encasing the great abdominal vessels (thin large arrows). Interterm Axial CT a
the previously noted amalgamated nodal mass (CT overstating), on the other h
SUV  12.6) denoting partial remission.biopsy procedure in indeterminate cases where
histopathology is mandatory (Table 4, Figs. 7 and 11).4. Discussion
CT is the most readily available and most commonly
used tool for staging lymphoma. Fundamental limitations
of CT are that recognition of lymph node involvement is
based solely on size and that detection of bone marrow
and extra-nodal tissue involvement may be limited. Inand B showed large nodal metabolically active 18-FDG avid amalgamated
nd axial PET CT images: C axial CT showed minimal changes in the size of
and PET-CT showed SUV  25 recorded at the aortic bifurcation site (max.
Fig. 11. 56 years old female: Pretreatment PET-CT showed no metabolically active FDG avid lesion in the duodenum A, follow-up interterm PET-CT images
axial B, coronal C and sagittal D showed newly developed lymphomatous lesions in the duodenum with max. SUV  26.6 denoting relapsing lymphoma.
1646 N.N. Omar et al. / The Egyptian Journal of Radiology and Nuclear Medicine 47 (2016) 1639–1647addition to depicting nodal sites of lymphoma with greater
accuracy than CT, PET/CT can detect the activity of the
lesion and has greater sensitivity for sites of extra-nodal
involvement and correspondingly has been found to
improve baseline staging compared with conventional
staging with CT alone [10]. Hodgkin’s lymphoma is 18F-
FDG PET/CT avid, and PET/CT is more accurate in initial
staging than CECT.
In this study out of the 12 cases came for initial staging,
18F-FDG PET/CT and CECT were concordant in staging of 9
cases (75%) while 18F-FDG PET/CT disagreed with CECT in
the initial staging of 3 cases (25%) where it upstaged 3
cases (25%) from stage II to IV. The concordant in staging
in our study between 18F-FDG PET/CT and CT was nearly
similar to that detected by Riad and Omar. They found a
73.2% concordance [11] and less than that of Pelosi et al.
who found a 12% upstaging by 18F-FDG PET/CT compared
to CT [12], and the additional value of 18F-FDG PET/CT
causing upstaging in our cases was not in detecting active
subcentimetric lymph nodes as in the study conducted by
Ranani et al. [13] but in detecting the extra-nodal thoracic
sites of disease that were not determined by CECT. Down-
staging of cases was documented in previous studies
[12,13], as they detected enlarged lymph nodes by CT
yet, not metabically active on PET/CT. No similar cases thatneeded downstaging were found in our study because our
patients had early stage lymphoma disease.
An important and valid application of 18F-FDG PET/CT
is to detect viable tumor in residual lesions after the treat-
ment of patients with HL and NHL. A residual mass at the
end of therapy is not a rare finding and is considered a clin-
ical challenge in HL and intermediate/high grade NHL
restaging. 18F-FDG PET/CT has proved to be much more
accurate in distinguishing fibrosis from viable tumor, since
fibrosis does not show high metabolic activity in contrast
to viable residual tumor [14]. This fact made FDG PET/CT
extremely useful for therapy response assessment.
Our study confirmed the value of 18F-FDG PET/CT in
initial staging and planning that involved field radiother-
apy. We showed that 18F-FDG PET/CT detected a 60% com-
plete regression ratio compared to only 14% by CT scan. In
the future this may be relied upon to minimize chemother-
apy cycles in favorable group of patients, hence reducing
the side effects of treatment [2].
In the follow-up study during chemotherapy cycles,
18F-FDG PET/CT and CECT were concurrent in results in
11 cases (61%) and discordant in 7 cases (39%). In the
follow-up study after the end of chemotherapy cycles,
18F-FDG PET/CT and CECT were concurrent in results in 9
cases (44%) and discordant in 11 cases (56%) in contradic-
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percentage between both modalities (90%) and less
disagreement [13].
Several studies compared CECT to 18F-FDG PET/CT in
detection of extra-nodal lymphoma; all were around 88%
sensitivity and 100% specificity for 18F-FDG PET/CT com-
pared to 50% sensitivity and 90% specificity with CECT
[3,13]. We reported 100% sensitivity and specificity for
PET-CT compared to 62.5% sensitivity and 97.6% specificity
for CECT in detection of extra-nodal disease sites.
18F-FDG PET/CT proved higher sensitivity and speci-
ficity over CECT in our study. The major strength of 18F-
FDG PET/CT over CECT was its higher ability for detection
of extra-nodal sites of lymphoma at initial staging and its
much higher ability to exclude active disease in residual
nodal mass lesions on follow-up studies. The use of early
response to therapy of lymphoma patients by 18F-FDG
PET/CT may tailor the dose of chemotherapy avoiding
unnecessary toxic treatment.
Limitation of the current study includes, high coast, rel-
atively small number of patients and relative short median
follow-up period.
5. Conclusion
18F-FDG PET/CT scan has become an important part of
the management of lymphoma, and been recommended
for staging, detection of recurrence, evaluation of response
to treatment, and prediction of response in patients with
lymphoma due to the high sensitivity and specificity rates.
Even though an interim PET scan possesses the predictive
value, its role in directing treatment remains investiga-
tional. Any alteration during the treatment should be con-
firmed by the biopsy.
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